Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.7452W HIGH $1.74
Volume
104.87 K
Value Traded
138.26 K
Short % Float
2.29%
-7.69%Week
-12.2%1 Month
+16.13%3 Month
0%6 Month
-85.14%5 Year
-64.24%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
33.96 M
EPS (TTM)
0.36
P/E Ratio
3.00
Ent. Value
-2.52 M
Total Shares
31.44 M
Float Shares
30.89 M
Insiders
1.77%
Institutions
16.83%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ATNM Catalyst Timeline
Dated clinical, regulatory and corporate events for Actinium Pharmaceuticals, Inc. (Delaware)
Catalyst Timeline
Dated clinical, regulatory & corporate events for Actinium Pharmaceuticals, Inc. (Delaware)
598Total events
6Upcoming
100Tier-1 (high impact)
2012 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Patent GrantedActimab-AIP / Competition
Canadian application 3,059,752 entered pre-grant status for Actimab-A + venetoclax combination in AML
acute myeloid leukemia (AML)source ↗
▲Manufacturing MilestoneActimab-ACMC / Inspection
IND amended to add additional manufacturer for Actimab-A
▲Other Regulator MilestoneEx-US Regulatory
NYSE Regulation accepted compliance plan and granted plan period through November 27, 2027
◆Oral PresentationATNM-400Presentation
Oral presentation of ATNM-400 data at SNMMI 2026
prostate cancersource ↗
◆Poster PresentationATNM-400Presentation
ATNM-400 poster on prostate cancer models at SNMMI 2026
prostate cancersource ↗
◆Poster PresentationPresentation
Poster on optimizing chelator-to-antibody ratio for 225Ac-labeled antibodies at SNMMI 2026
▲Patent GrantedActimab-AIP / Competition
Canadian patent allowance for Actimab-A + CLAG-M combination in AML
acute myeloid leukemia (AML)source ↗
▲Patent GrantedIomab-ACTIP / Competition
Canadian patent allowance for Iomab-ACT conditioning approach
gene-edited cell-based therapiessource ↗
▼Restructuring LayoffsCorporate
NYSE American notice of non-compliance with continued listing standards
▲Poster PresentationATNM-400Presentation
Preclinical data for ATNM-400 presented at AACR 2026
solid tumors (prostate, lung, breast cancer)source ↗
◆Oral PresentationActimab-APresentation
Actimab-A data presented at AACR 2026 Annual Meeting
acute myeloid leukemia (AML)source ↗
◆Poster PresentationATNM-400Presentation
ATNM-400 poster presentation at AACR 2026
solid tumorssource ↗
◆Poster PresentationActimab-APresentation
Actimab-A poster presentation at AACR 2026
acute myeloid leukemiasource ↗
◆AbstractPresentation
Abstracts for ATNM-400 and Actimab-A to be released via AACR Online Program Planner
◆Poster PresentationATNM-400Presentation
Poster presentation at SABCS 2025 showing preclinical data for ATNM-400 in breast cancer
breast cancersource ↗
◆Poster PresentationATNM-400Presentation
Poster presentation of ATNM-400 preclinical data in hormone-resistant and HER2-resistant breast cancer at SABCS 2025
breast cancersource ↗
▲Preclinical PoCATNM-400Preclinical
Preclinical data demonstrating potent efficacy in TNBC and ability to overcome endocrine and HER2-targeted therapy resistance
triple-negative breast cancersource ↗
◆Topline ReadoutActimab-AClinical Data
Initial clinical data for Actimab-A triplet combination in frontline AML
frontline acute myeloid leukemiasource ↗
◆Poster PresentationATNM-400Presentation
Preclinical data of ATNM-400 in NSCLC presented at AACR-NCI-EORTC International Conference
non-small cell lung cancer (NSCLC)source ↗
▲Preclinical PoCATNM-400Preclinical
ATNM-400 shows superior efficacy vs osimertinib, Dato-DXd, amivantamab in preclinical NSCLC models
non-small cell lung cancer (NSCLC)source ↗
◆Poster PresentationATNM-400Presentation
Poster presentation of ATNM-400 preclinical data in NSCLC at AACR-NCI-EORTC
non-small cell lung cancersource ↗
◆Poster PresentationATNM-400Presentation
Poster presentation of ATNM-400 preclinical data at 32nd Annual PCF Scientific Retreat
metastatic castration-resistant prostate cancer (mCRPC)source ↗
◆Poster PresentationATNM-400Presentation
Preclinical data presented at 4th Annual Targeted Radiopharmaceuticals Summit
prostate cancersource ↗
◆Preclinical PoCATNM-400Preclinical
Additional preclinical data expected in second half of 2025
prostate cancersource ↗
◆Topline ReadoutIomab-ACTClinical Data
Initial clinical data from Iomab-ACT commercial CAR-T trial expected
CAR-T conditioningsource ↗
◆Timing GuidanceActimab-APresentation
Clinical outcomes expected starting in second half of 2025
acute myeloid leukemiasource ↗
◆Poster PresentationATNM-400Presentation
Preclinical data presented at SNMMI annual meeting
prostate cancersource ↗
▲First Patient DosedIomab-ACTTrial
First patient enrolled in Iomab-ACT commercial CAR-T trial at UT Southwestern
CAR-T conditioningsource ↗
▲Preclinical PoCATNM-400Preclinical
Preclinical data presented at AACR showing ATNM-400 more efficacious than Pluvicto and active after Pluvicto resistance
prostate cancersource ↗
●Oral PresentationATNM-400Presentation
AACR Annual Meeting presentation of ATNM-400 preclinical data
prostate cancersource ↗
▲Poster PresentationActimab-APresentation
AACR 2025 poster presentation on Actimab-A mutation agnostic antileukemic activity in AML models
acute myeloid leukemiasource ↗
◆Trial InitiationActimab-ATrial
First clinical trial under CRADA evaluating Actimab-A + Venetoclax + ASTX-727 in frontline AML
acute myeloid leukemiasource ↗
◆Oral PresentationATNM-400Presentation
Initial preclinical data for ATNM-400 to be presented at AACR
prostate cancersource ↗
◆Timing GuidanceActimab-APresentation
Clinical data expected in second half of 2025
acute myeloid leukemiasource ↗
◆Topline ReadoutActimab-AClinical Data
Initial clinical data expected from Actimab-A triplet combination trial
frontline acute myeloid leukemia (AML)source ↗
◆Trial InitiationIomab-ACTTrial
Iomab-ACT commercial CAR-T trial to initiate patient enrollment
cell and gene therapy conditioningsource ↗
◆Topline ReadoutIomab-ACTClinical Data
Clinical data from Iomab-ACT sickle cell disease trial expected
sickle cell diseasesource ↗
▲Preclinical PoCATNM-400Preclinical
99.8% tumor growth inhibition achieved with single dose of ATNM-400 in preclinical prostate cancer models
prostate cancersource ↗
▲Trial InitiationActimab-ATrial
Initiated Actimab-A solid tumor program with PD-1 inhibitors in HNSCC
head and neck squamous cell carcinomasource ↗
▲Full ResultsActimab-AClinical Data
Results of Actimab-A + CLAG-M published in Leukemia
relapsed/refractory acute myeloid leukemiasource ↗
▲Partnership / LicenseCorporate
Supply agreement with Exckert & Ziegler for Actinium-225 Radioisotope
●AbstractActimab-APresentation
Abstracts accepted for presentation at AACR highlighting Actimab-A's mutation agnostic profile in AML
acute myeloid leukemiasource ↗
◆Oral PresentationPresentation
KOL investor call to highlight revamped clinical programs and expanded market opportunities
Past FDA Catalysts and PDUFA Decisions
How ATNM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-04-30 | ATNM-400 | Pre-clinical data readout | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D36 / 100
Pipeline Score
$18M
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.5x
rNPV / MCap
Top 50%
Micro Cap(rank 329 of 658)
Percentile Rank
Actinium Pharmaceuticals, Inc. (Delaware) faces pipeline headwinds (36/100), with $569M risk-adjusted pipeline value, led by 131I-apamistamab in Acute Leukemia (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 131I-apamistamab Monoclonal antibodyNCT07157514 | Acute Leukemia | Phase 3 | NOT YET_RECRUITING | 306 | Feb 1, 2034 |
Clinical Trial Results
Readouts, endpoints and source filings for every ATNM program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Actimab-A | acute myeloid leukemia (AML) | 2026-04-22 | significant AML cell killing; robust cytotoxicity observed in primary AML patient samples across key mutations (FLT3, KMT2A, NPM1, IDH1, IDH2, or TP53); demonstrated compelling clinical activity and a manageable safety profile in more than 150 AML patientsRead More | Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual MeetingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| SETH SANDESHDirector, Officer (Chief Executive Officer) | Grant/Award | 300,000 305,381 held | $0.00 | 08/17/2022 |
Hedge Fund 13F Activity
Hedge Funds invested in ATNM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SILVERARC CAPITAL MANAGEMENT, LLC | 0.2 % | 350.00 K | 45.91 K |
ATNM Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-05-21 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ATNM ranks across every disease it competes in
Competitive Position is a premium feature
See how ATNM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialATNM News
ATNM▲ +19.4%on this news· ran to +36% by day 3
Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Actinium Pharmaceuticals, Inc. will present at the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026. CEO Sandesh Seth will lead the presentation, and management will be available for one-on-one meetings with investors. The company focuses on developing targeted radiotherapies aimed at improving cancer treatment outcomes.
Read more →ATNMActinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update
Actinium Pharmaceuticals has announced significant advancements in its Actimab-A program, including new patents and expanded manufacturing capacity. These developments are aimed at supporting upcoming clinical milestones in the treatment of hematological malignancies and solid tumors. Additionally, the company has received an extension from NYSE American to regain compliance with listing standards until November 2027.
Read more →ATNMActinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models
Actinium Pharmaceuticals showcased new findings on ATNM-400 during the SNMMI 2026 Annual Meeting. The data suggests that ATNM-400 may effectively overcome resistance to all three approved androgen receptor inhibitors in prostate cancer. Additionally, the presentation emphasized the drug's flexible and well-tolerated dosing in relevant cancer models.
Read more →ATNMActinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer
Actinium Pharmaceuticals presented new preclinical data on its investigational treatment, ATNM-400, at the SNMMI 2026 Annual Meeting. The results show that ATNM-400 not only outperformed existing KRAS inhibitors but also demonstrated potent synergy with EGFR-targeting osimertinib, achieving complete tumor regression in models. This positions ATNM-400 as a prospective mutation-agnostic therapy in non-small cell lung cancer (NSCLC), addressing a significant portion of cases where traditional mutation-specific therapies fall short. The data reinforces Actinium's strategy to develop a broadly effective treatment capable of overcoming tumor resistance.
Read more →ATNM▼ -6.3%on this newsshared move
Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates
Actinium Pharmaceuticals presented new radiochemistry data at the SNMMI 2026 Annual Meeting, showcasing the benefits of optimizing the chelator-to-antibody ratio (CAR) in Actinium-225 radioconjugates. The study found that lower-CAR conjugates maintained effective tumor targeting while decreasing off-target uptake in the liver and spleen, thus broadening the therapeutic window. These results underscore Actinium's advanced radiochemistry capabilities and the implications for enhancing the safety and effectiveness of their drug candidates. The findings may significantly influence the design of future radioconjugates in their pipeline.
Read more →ATNM▼ -6.3%on this newsshared move
Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development
Actinium Pharmaceuticals has appointed Dr. Steffen Heeger as Chief Medical Officer to enhance its development pipeline. Dr. Heeger comes with significant experience in oncology and has been instrumental in successful drug approvals, including the blockbuster Erbitux®. His leadership is anticipated to advance Actinium's projects, including Actimab-A and ATNM-400, as the company prepares for critical clinical trials in the latter half of 2026. Actinium aims to leverage Dr. Heeger's expertise to further its goal of creating effective targeted radiotherapies.
Read more →ATNM▼ -6.3%on this newsshared move
Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs
Actinium Pharmaceuticals has received Notices of Allowance for two patent applications from the Canadian Intellectual Property Office, enhancing its intellectual property protection for the Actimab-A and Iomab-ACT programs. These patents cover innovative treatments for hematologic malignancies and gene-edited cell-based therapies. The company aims to expand its global patent estate, which now includes approximately 250 patents.
Read more →ATNM▼ -6.3%on this newsshared move
Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice
Actinium Pharmaceuticals announced an update on its ATNM-400 program, showcasing new data at the SNMMI 2026 Annual Meeting. The presentations will highlight ATNM-400's efficacy in treating prostate cancer and non-small cell lung cancer. Additionally, the company received a notice from NYSE American regarding non-compliance with listing standards, prompting the need for a compliance plan.
Read more →ATNMActinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization
Actinium Pharmaceuticals announced three upcoming presentations at the SNMMI 2026 Annual Meeting, showcasing the potential of ATNM-400 in treating non-small cell lung cancer (NSCLC) and prostate cancer. The data highlights ATNM-400's ability to function as a mutation-agnostic therapy and its effectiveness in PSMA-negative prostate cancer. Additionally, advancements in the radioconjugate's optimization are expected to enhance its therapeutic index.
Read more →ATNM▼ -7.9%on this news· ran to -20% by day 3
Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting
Actinium Pharmaceuticals highlighted the anti-leukemic activity of Actimab-A at the AACR Annual Meeting, emphasizing its mutation-agnostic approach in treating acute myeloid leukemia (AML). Data indicated that Actimab-A combinations led to significant AML cell killing, independent of mutation status, by promoting transcriptional reprogramming. The findings suggest enhanced efficacy when paired with standard-of-care therapies, reinforcing Actimab-A's potential as a universal combination backbone in AML treatment. Additionally, the safety profile observed in previous clinical studies supports its further development as a foundational therapy.
Read more →ATNM▼ -7.9%on this news· ran to -20% by day 3
Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting
Actinium Pharmaceuticals, Inc. has announced promising preclinical data for its novel targeted radiotherapy, ATNM-400, presented at the American Association for Cancer Research Annual Meeting. The data demonstrates the treatment's broad efficacy across various cancer models, including prostate, lung, and breast cancers, outperforming existing therapies in several cases. Notably, ATNM-400 is well tolerated with no significant toxicities observed, enhancing its development potential. The findings suggest that ATNM-400 could provide new options for patients with treatment-resistant tumors.
Read more →ATNM▲ +11.2%on this news
Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting
Actinium Pharmaceuticals has announced new preclinical data for ATNM-400 and Actimab-A, highlighting their potential in treating solid tumors and acute myeloid leukemia (AML), respectively. The data will be presented at the AACR Annual Meeting 2026 in San Diego, showcasing ATNM-400's activity against tumors resistant to targeted therapies and Actimab-A's mutation-agnostic efficacy. Both compounds are positioned to provide significant advancements in cancer treatment, with presentations scheduled for April 21, 2026. The findings are part of Actinium's broader strategy to develop innovative radiotherapies.
Read more →ATNMActinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting
Actinium Pharmaceuticals, Inc. (ATNM) has announced the presentation of two abstracts at the 2026 AACR Annual Meeting, scheduled for April 17-22 in San Diego. The presentations will focus on the company's innovative targeted radiotherapies, particularly the ATNM-400 program which targets various cancers including prostate, lung, and breast cancers. The event marks an important opportunity for Actinium to engage with the oncology research community, showcasing their progress in differentiated radiotherapy development. Specific abstract details will be released on March 17, 2026, in accordance with AACR guidelines.
Read more →ATNMActinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025
Actinium Pharmaceuticals presented new preclinical data for ATNM-400 at the 2025 SABCS, showcasing its strong anti-tumor activity against various breast cancer subtypes, including hormone receptor-positive and triple-negative cancers. The data highlight ATNM-400's potential as a treatment option for patients resistant to standard therapies. The findings support further development of ATNM-400 as a monotherapy or in combination with other treatments.
Read more →ATNMActinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium
Actinium Pharmaceuticals announced promising preclinical data for ATNM-400, a targeted radiotherapy for triple-negative breast cancer and other types. The data, to be presented at the San Antonio Breast Cancer Symposium, indicates strong anti-tumor effects in models resistant to standard therapies. ATNM-400's unique mechanism may offer new hope for patients with limited treatment options.
Read more →ATNMActinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications
Actinium Pharmaceuticals will present new preclinical data for ATNM-400 at the 2025 San Antonio Breast Cancer Symposium. The data highlights the efficacy of ATNM-400 in hormone-resistant and HER2-resistant breast cancer, as well as its potential across prostate cancer and non-small cell lung cancer. This therapy aims to address significant unmet needs in these oncology indications.
Read more →ATNMActinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference
Actinium Pharmaceuticals, Inc. announced that its CEO, Sandesh Seth, will participate in the Stephens Biotechnology Virtual Fireside Chat on November 4, 2025. The event will also provide opportunities for one-on-one meetings with investors. Actinium is known for its targeted radiotherapies, including its lead candidate ATNM-400, which shows promise in treating prostate cancer and non-small cell lung cancer.
Read more →ATNM▼ -8.4%on this news
Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Actinium Pharmaceuticals announced promising preclinical data for ATNM-400, a novel radioconjugate targeting non-small cell lung cancer (NSCLC). The data presented at the AACR-NCI-EORTC conference showed that ATNM-400 exhibited superior efficacy, achieving 3-5 times greater tumor growth inhibition compared to existing therapies. Additionally, the combination of ATNM-400 with osimertinib resulted in complete tumor regression in all tested subjects, highlighting its potential as a first-in-class treatment.
Read more →ATNM▲ +5.7%on this newsshared move
Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat
Actinium Pharmaceuticals presented promising preclinical data for ATNM-400 at the 32nd Annual Prostate Cancer Foundation Scientific Retreat. This first-in-class radiotherapy targets a novel antigen and demonstrated superior efficacy compared to PSMA-targeted therapies. Notably, ATNM-400 achieved complete tumor regression in a significant percentage of animal models, showcasing its potential in treating resistant prostate cancer.
Read more →ATNMActinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Actinium Pharmaceuticals announced that preclinical data for ATNM-400 in non-small cell lung cancer (NSCLC) will be presented at the AACR-NCI-EORTC conference. This first-in-class Actinium-225 radiotherapy shows promise in overcoming resistance to osimertinib, potentially transforming treatment for patients with EGFR-mutant NSCLC. The drug also demonstrates significant efficacy in prostate cancer.
Read more →About Actinium Pharmaceuticals, Inc. (Delaware)
Headquarters100 PARK AVE., 23RD FLOOR, NEW YORK, NY, 10017
Founded27-12-2012
BIOPHARMAWATCH ELITE PLUS
Trade the next ATNM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime